FCGR3A and acute myeloid leukemia: Studies have shown that by using a tri‐specific molecule targeting CLEC12A on AML cells and activating NK cells with a humanized anti‐CD16 single‐domain antibody and IL‐15, the NK cell‐mediated response has a strong effect on primary patient‐derived AML blasts.